SCOPE 2023: Biospecimen Presentation Questions & Insights
Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Hope Meely, chief clinical officer at Slope, elaborates on the feedback she received surrounding her conference presentation, "The Hidden Regulatory Risk from Sample Management — What Should You Be Aware of?” This includes the agreement among attendees that the clinical trials industry needs to ensure that biospecimens are managed, especially since they are the driving factors of safety and efficacy data.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.
